Citation Impact
Citing Papers
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
2008 Standout
Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non–Small-Cell Lung Cancer
2010 Standout
Carotenoids: biochemistry, pharmacology and treatment
2016 Standout
Curcumin: A review of anti-cancer properties and therapeutic activity in head and neck squamous cell carcinoma
2011
The DNA-damage response in human biology and disease
2009 StandoutNature
An epigenetic mechanism for capecitabine resistance in mesothelioma
2009
Mechanism-based Pharmacokinetic/Pharmacodynamic Meta-analysis of Trabectedin (ET-743, Yondelis) Induced Neutropenia
2007
Marine natural products
1990 Standout
Phytochemicals in Cancer Treatment: From Preclinical Studies to Clinical Practice
2020 Standout
The evolution of cancer research and drug discovery at Lilly Research Laboratories
2005
Cancer drug resistance: an evolving paradigm
2013 Standout
Head and neck cancer
2008 Standout
Pemetrexed Improves Tumor Selectivity of 111In-DTPA-Folate in Mice with Folate Receptor–Positive Ovarian Cancer
2008
Development and validation of an improved liquid chromatography–mass spectrometry method for the determination of pemetrexed in human plasma
2009
Natural products to drugs: natural product-derived compounds in clinical trials
2008 Standout
Nasopharyngeal carcinoma
2015 Standout
Analysis of anticancer drugs: A review
2011 Standout
Classification of anticancer drugs—a new system based on therapeutic targets
2003
Treatment of Acute Lymphoblastic Leukaemia
2007
Liposomal drug delivery systems: From concept to clinical applications
2012 Standout
A phase II study of pemetrexed combined with cisplatin in patients with recurrent or metastatic nanopharyngeal carcinoma
2011
The Chemistry of Curcumin: From Extraction to Therapeutic Agent
2014 Standout
A Phase I Study of Pemetrexed, Carboplatin, and Concurrent Radiotherapy in Patients with Locally Advanced or Metastatic Non–Small Cell Lung or Esophageal Cancer
2007
Coordinating Radiometals of Copper, Gallium, Indium, Yttrium, and Zirconium for PET and SPECT Imaging of Disease
2010 Standout
Marine natural products
2015 Standout
Pemetrexed Combined with Oxaliplatin or Carboplatin as First-Line Treatment in Advanced Non–Small Cell Lung Cancer: A Multicenter, Randomized, Phase II Trial
2005
Turmeric (Curcuma longa) and its major constituent (curcumin) as nontoxic and safe substances: Review
2018 Standout
Chemotherapy Options for Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck
2006
Kinase Inhibitors of Marine Origin
2013
Works of Jane E. Latz being referenced
A phase II study of enzastaurin in combination with erlotinib in patients with previously treated advanced non-small cell lung cancer
2012
Population pharmacokinetic analysis of ten phase II clinical trials of pemetrexed in cancer patients
2005
A semimechanistic-physiologic population pharmacokinetic/pharmacodynamic model for neutropenia following pemetrexed therapy
2005
Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck
2001
Clinical application of a semimechanistic-physiologic population PK/PD model for neutropenia following pemetrexed therapy
2005
A phase I dose-escalation and pharmacokinetic study of enzastaurin and erlotinib in patients with advanced solid tumors
2011
Phase I and pharmacokinetic study of the multitargeted antifolate pemetrexed in combination with oxaliplatin in patients with advanced solid tumors
2004
Pharmacokinetic evaluation of platinum derived from cisplatin administered alone and with pemetrexed in head and neck cancer patients
2008
Phase I and Pharmacokinetic Study of Pemetrexed Administered Every 3 Weeks to Advanced Cancer Patients With Normal and Impaired Renal Function
2006
A phase I/II study of pemetrexed and vinorelbine in patients with non-small cell lung cancer
2005